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The transcriptional activity of estrogen receptor- is
controlled by coregulators. MTA1 (metastasis-associat-
ed protein 1) represses estrogen receptor--driven tran-
scription by recruiting histone deacetylases (HDACs) to
the estrogen response element containing target gene
chromatin in breast cancer cells. Using a yeast two-
hybrid screen with the MTA1 C-terminal domain as bait,
we identified MAT1 (me´nage a´ trois 1) as an MTA1-bind-
ing protein. MAT1 is an assembly/targeting factor for
cyclin-dependent kinase-activating kinase (CAK), which
has been shown to functionally interact with general
transcriptional factor TFIIH, a known inducer of ER
transactivation. We show that estrogen signaling pro-
motes nuclear translocation of MAT1 and that MTA1
interacts with MAT1 both in vitro and in vivo. MAT1
binds to the C-terminal 389–441 amino acids GATA do-
main and N-terminal 1–164 amino acids bromo-domain
of MTA1, whereas MTA1 binds to the N-terminal ring
finger domain of the MAT1. In addition, MAT1 interacts
with the activation function 2 domain of ER and colo-
calizes with ER in activated cells. MTA1 deregulation in
breast cancer cells led to its interactions with the CAK
complex components, ER, and HDAC2. Accordingly,
MTA1 inhibited CAK stimulation of ER transactivation
that was partially relieved by HDAC inhibitor trichosta-
tin A, suggesting that MTA1 might inhibit CAK-induced
transactivation function of ER by recruiting HDAC. Fur-
thermore, MTA1 overexpression inhibited the ability of
CAK complex to phosphorylate ER. Together, these find-
ings identified MAT1 as a target of MTA1 and provided
new evidence to suggest that the transactivation func-
tions of ER might be influenced by the regulatory inter-
actions between CAK and MTA1 in breast cancer cells.
The eukaryotic genome is compacted with histone and other
proteins to form chromatin, which consists of repeating units of
nucleosome (1, 2). Formation of nucleosomes and higher order
chromatin structures can render the DNA inaccessible to tran-
scription factors and complexes. For transcription factors to
access DNA, the repressive chromatin structure needs to be
remodeled. Dynamic alterations in the chromatin structure can
facilitate or suppress the access of the transcription factors to
nucleosomal DNA, leading to transcriptional regulation. One
way to achieve this is through alterations in chromatin remod-
eling factors or in the acetylation state of nucleosomal histones
(3–5). Acetylation of core histones occurs at lysine residues on
the N-terminal tails of the histones, thus neutralizing the
positive charge of the histone tails and decreasing their affinity
for DNA. Hyperacetylated chromatin is generally associated
with transcription activation, whereas hypoacetylated chroma-
tin is associated with transcription repression (3–6).
A number of recent studies have raised the possibility of a
close connection between HDACs1 and cancer. Because HDAC-
mediated deacetylation of nucleosomal histones is known to be
associated with transcriptional repression of some genes, it is
being proposed that the deregulation of recruitment of HDAC-
containing repressor complex to specific target promoters could
serve as a potential mechanism by which these enzymes con-
tribute to tumorigenesis. For example, MTA1 (metastasis-as-
sociated protein 1) represses estrogen receptor- (ER)-driven
transcription by recruiting HDAC to the ER response element
(ERE)-containing target gene chromatin in breast cancer cells
(7). The NuRD-70 polypeptide of nucleosome remodeling/
HDAC complex is identical to that of the MTA1 (8–11). The
MTA1 gene was initially identified by differential expression in
rat mammary adenocarcinoma metastatic cells, and its expres-
sion has been shown to correlate well with the metastatic
potential of several human cell lines and tumors (12).
To better understand the cellular functions of MTA1 in
breast cancer cells, we performed a yeast two-hybrid screen to
clone MTA1-interacting proteins. One of several isolates was
identified as MAT1 (me´nage a´ trois 1). MAT1 was originally
discovered as an integral component of the cyclin-dependent
kinase (CDK7)-activating kinase (CAK), a complex consisting
of catalytic subunit CDK7, regulatory subunit cyclin H, and
MAT1 (13). The MAT1 protein consists of three major motifs:
the N-terminal RING finger region, the central coiled-coil re-
gion, and the C-terminal cyclin-like region (13–16). The func-
tions of MAT1 are mediated by interactions of these motifs with
distinct protein-protein interactions. For example, the RING
finger domain is linked with general transcription factor
TFIIH-mediated transcription (17), the coiled-coil domain in
making contact with TFIIH via XPB and XPD helicase sub-
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units (18), and the cyclin-like region in the formation of tri-
meric CDK7-cyclin H-MAT1 complex (19). MAT1 facilitates the
formation of the ternary CAK complex by assembling and sta-
bilizing the interactions between the CDK7 and cyclin H with-
out involving the activating phosphorylation in the T-loop of
human CDK7 (20). MAT1 has been also shown to determine
the substrate specificity of CAK, because recruitment of MAT1
to the CDK7/cyclin H as a part of TFIIH preferentially targets
the RNA polymerase II large subunit over CDK2 (21). In addi-
tion, MAT1 as a part of CDK7-cyclin H-MAT1 complex within
the context of TFIIH enhances the phosphorylation of several
in vitro substrates, including the POU domain of octamer tran-
scription factor (22), tumor suppressor p53, and pRB proteins
(23, 24), retinoic acid receptor- (25, 26), and estrogen recep-
tor- (27). In addition, MAT1 also binds to XPB and XPD
helicases subunits of TFIIH that recruit CAK complex to the
core TFIIH (27). These observations suggest that MAT1 as a
part of CAK in conjunction with multi-enzymatic protein com-
plex TFIIH participates in several fundamental aspects of the
transcription regulation. Because RING finger and coiled-coil
motifs are generally involved in protein-protein interactions,
MAT1 could potentially interact with other cellular regulatory
proteins.
Here, we show that MTA1 directly binds to the MAT1 and
represses CAK-mediated stimulation of ERE transcription and
that MAT1 interacts with ER in a ligand-independent manner.
In addition, MAT1 is frequently up-regulated in human breast
tumors. These findings reveal a novel connection among MTA1,
MAT1, and cancer and discovered the existence of regulatory
interactions between MTA1 and CAK in breast cancer cells.
MATERIALS AND METHODS
Cell Cultures and Reagents—MCF-7, MDA-MB-231, T47-D, MDA-
MB-453, BT-474, and ZR-75 human breast cancer cells (7, 28) were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum. The following antibodies were used: anti-MAT1,
anti-MTA1, anti-cyclin H, anti-CDK7, and anti-HDAC1 (Santa Cruz
FIG. 1. Identification of MAT1 as an
MTA1-binding protein. A, yeast cells
were cotransfected with GAD-MAT1 and
GBD control vector, or GBD-MTA1 (ami-
no acids 1–715) or GBD-ctMTA1 (amino
acids 255–715), or GBD-ntMAT1 (amino
acids 1–173). Cotransformants were
plated on selection plates lacking leucine
and tryptophan (LT) (middle panel) or
lacking adenine, histidine, leucine, and
tryptophan (AHLT) (bottom panel).
Growth was recorded after 72 h. For -ga-
lactosidase assay, filter lift assays were
performed. A blue color indicates the spe-
cific interaction of two proteins (top pan-
el). B, MAT1 interaction in the GST pull-
down assays. In vitro translated 35S-
labeled MAT1 protein was incubated with
either MTA1-GST or GST (left panel), or
in vitro translated 35S-labeled MTA1 pro-
tein were incubated with either MAT1-
GST or GST (right panel) and analyzed by
SDS-PAGE and autoradiography. C,
MCF-7 cells were cotransfected with Myc-
MTA1 and T7-MAT1 or by T7-MAT1 and
the pCMV vector. The cells were lysed
after 36 h, immunoprecipitated with an-
ti-T7 monoclonal antibody, resolved on
10% SDS-PAGE, and immunoblotted
with anti-T7 and anti-Myc antibody. D, in
vitro interaction between T7-MTA1 and
MAT1. MCF-7/pCDNA and MCF-7/
MTA1-T7 cells grown in 10% serum were
lysed, and lysates containing equal
amount of protein were immunoprecipi-
tated with an anti-MAT1 monoclonal an-
tibody and immunoblotted with antibod-
ies against T7 and MAT1. E, endogenous
MTA1 interacts with endogenous MAT1.
Total protein from T47D cells was immu-
noprecipitated with anti-MTA1 antibody
and immunoblotted with antibodies
against either MAT1 or MTA1. F, MTA1
colocalizes with MAT1. MCF-7 cells were
transiently transfected with c-Myc-
MTA1, and fixed in methanol and immun-
ofluorescently stained for c-Myc tag
(green) and MAT1 (red) and counter-
stained for nuclear DNA (blue). Areas of
colocalization of the red and green signals
show yellow fluorescence (40 magnifica-
tion). C-ter, C-terminal; N-ter, N-termi-
nal; IP, immunoprecipitation; Fl, full
length; W, Western blot.
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Biotechnology, Santa Cruz, CA), anti-T7 (Novagen, Milwaukee, WI),
anti-HER-2 (NeoMarkers, Fremont, CA), anti-vinculin (Sigma), an-
ti-ER (Upstate Biotechnology, Lake Placid, NY), and anti-mouse horse-
radish peroxidase conjugate (Amersham Biosciences). Alexa 546-la-
beled goat anti-rabbit and Alexa 488-labeled goat anti-mouse secondary
antibodies and the DNA-intercalating fluorescent dye ToPro3 were
purchased from Molecular Probes (Eugene, OR).
Plasmid Construction and Two-hybrid Library Screening—The full-
length MTA1 (1–715 amino acids) (7) was digested with BamHI and
XbaI (blunt end) and ligated to the pGBKT7 vector that expresses
protein fused to amino acids 1–147 of the GAL4-DNA binding domain at
BamHI and PstI (blunt end) (Clontech). MTA1 baits were constructed
by deleting 1–254 amino acids from the N terminus of MTA1 by cutting
and self-ligating with NcoI. The remaining 255–715 amino acids of the
C terminus of MTA1 was used as bait. This bait was used to screen a
human mammary gland cDNA library fused to the Gal4 activation
domain (Clontech) according to the manufacturer’s instructions. A total
of 2  106 clones were screened. The positive clones were isolated and
sequenced at the University of Texas M. D. Anderson Cancer Center
Core sequencing facility. The positive clones were also verified by one-
on-one transformations and selection on agar plates lacking adenine,
histidine, tryptophan, and leucine and also by -galactosidase assay
(28).
Deletion Constructs of MTA1 and MAT1—Nine MTA1 deletion con-
structs were generated to map the binding site(s) of MTA1 with MAT1
by PCR-based procedure. Starting from the N-terminal region, the
constructs were named N1-MTA1 to N9-MTA1. All of the forward (F)
primers including the ATG start codon primer contain an EcoRI site
and all of the reverse (R) primers including the stop codon (TAG) primer
contain a SalI site. The ATG start codon primer is 5-GCCGCCGGAAT-
TCACATGGCCGCCAACA-3and the stop codon (TAG) primer was 5-
AGGTGGGGGTCGACCCTAGTCCTCCCG-3. The construction of N1-
MTA1 through N7-MTA1 used the ATG start codon primer plus N1R,
5-ACTCGAATGTCGACTTTATCTGCCA-3; N2R, 5-AGCTGCTG-
CAGTCGACGGCCCGTGCGA-3; N3R, 5-AGGCCCGGCCGTCGA-
CAGGGCTCTGGCCCGG-3; N4R, 5-ACTGCGGTGTCGACCTGGC-
CTCTCTCCA-3; N5R, 5-ACCGAAGCACGTCGACCAGCGGCTT-3;
FIG. 2. MAT1 expression in different cells and normal mouse
tissues. A, MTA1 expression in human breast cancer cells. B, MAT1
expression in normal mouse tissues was detected by immunoblotting
with the indicated antibodies. C, MTA1 expression during the different
stages of murine mammary gland development. V, virgin; P, pregnancy;
L, lactation; PW, post-weaning. Numbers represent days.
FIG. 3. MAT1 expression in human breast tumors. A, paired breast tumors (T) and adjacent normal (N) tissue were analyzed by
immunoblotting with the indicated antibodies. B, densitometric quantitation of MTA1 and MAT1 signals. C, representative immunohistochemical
staining for MAT1 in tissues from normal and tumor sections. The tumor section shows both nuclear and cytoplasmic staining.
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and N6R, 5-TCAGGCGCACGTCGACGGGGTAGGACT-3, respec-
tively. The N7-MTA1 was constructed by using N7F, 5-ACCTTCGGAAT-
TCCCCTGGACTGCA-3, and N3R primers. For the construction of N8-MTA1
(422–715 amino acids) and N9-MTA1 (542–715 amino acids), we used
stop codon primer and N8F, 5-TGATGGAGGAATTCCAGGACCAAAC-
3, and N9F, 5-GAAGCCGTGCGAATTCATCTTGAGA-3, respectively.
All of the PCR products were run into 0.8% agarose gel, purified by
Geneclean or Mermaid (Bio 101, Inc., Vista, CA), cut with EcoR1 plus
SalI, and ligated to pGEX-5X vector at EcoR1 and XhoI site. After
confirming the sequences, these constructs were cut at EcoRI and NotI
site and ligated with pcDNA3.1A vector at EcoR1 and NotI site for the
T7 tag protein (29). The sequence of N10-MTA1 deletion construct
(amino acids 212–715) has been described previously (28).
A similar PCR-based procedure was used to generate eight deletion
constructs of MAT1. Four of five deletion constructs were made for
MAT1 using either start codon primer 5-GGGAATTCCCATGGAC-
GATCAGGGT-3 or stop codon primer 5-CTTATGTCGACTTAA CT-
GGGCTGCCA-3. The following constructs were made by PCR with
start codon primer plus 189R (1–189 amino acids), 5-GCAGAGCAA-
CAGCGGCCGCAGAAC TCTCCAGCTCAT-3; 114R (1–114 amino ac-
ids), 5-TCTTTTTGGTGGCGGCCGCATCCACATTGTTG-3; 66R (1–66
amino acids), 5-CAACCTCCTTGGCGGCCGCGGGATCTTCAAAGA-
3; and using stop codon primer plus 189F (189–309 amino acids),
5-GATGAGCTGGGAATTCCTGATCTCCCTGTTGCT-3. The amino
acids 114–189 construct was made using the primers 114F, 5-ACTT-
GACCAACAGAATTCATTTGGACAACACCA-3, and 189R. After Gene-
clean, the PCR products were digested with either EcoR1 and SalI or
EcoR1 and NotI and ligated to a pcDNA 3.1A vector at either EcoRI and
XhoI or EcoRI and NotI.
Transfection, Cell Extracts, and Immunoprecipitation—Transfection
was performed with a FuGENE 6 kit (Roche Molecular Biochemicals)
according to the manufacturer’s instructions. The cells were lysed with
RIPA buffer supplemented with 100 mM NaF, 2 mM NaVO5, 1 protease
mixture (Roche Molecular Biochemicals) on ice for 15 min. Cell lysates
containing equal protein were immunoprecipitated with the desired
antibody and analyzed by SDS-PAGE (28, 29).
CAK Phosphorylation of ER—The effect of MTA1 on CAK phospho-
rylation of ER was determined according to Chen et al. (27). Briefly,
MCF-7 cells stably expressing either pcDNA or T7-MTA1 were trans-
fected with CDK7 and MAT1 and labeled with [32P]orthophosphoric
acid. The cell lysates were immunoprecipitated with an anti-ER anti-
body, and the status of phosphorylated ER was analyzed by
autoradiography.
Chromatin Immunoprecipitation (ChIP) Assay—Approximately 106
cells were treated with cross-linked histones to DNA. The ChIP assay
was performed as described (7). After immunoprecipitation with corre-
sponding antibodies, the eluted DNA was amplified by PCR using the
primers GAATTAGCTTAGGCCTAGACGGAATG (forward) and AG-
GATTTGCTGATAGACAGAGACGAC (reverse) for pS2 promoter
around the ERE site.
Tissue Samples and Western Blotting—Mouse tissue samples were
collected and snap frozen in liquid nitrogen as described previously (7,
30). Human breast tissue samples were obtained from the University of
Texas M. D. Anderson Breast Tumor Core Pathology Laboratory main-
tained by Aysegul A. Sahin (31, 32). Thawed tissue samples were
homogenized in Triton X-100 lysis buffer (20 mM HEPES, 150 mM NaCl,
1% Triton X-100, 0.1% deoxycholate (v/w), 2 mM EDTA, 2 mM NaVO5,
and protease inhibitor mixture), and equal amounts of protein were
analyzed by Western blotting. The protein vinculin was used routinely
as a loading control.
In Vitro Transcription, Translation, and GST Pull-down Assays—In
vitro transcription and translation of the test proteins were performed
by using the TNT transcription-translation system (Promega). One
microgram of desired DNA in pCDNA 3.1 vector (Invitrogen) was trans-
lated in the presence of [35S]methionine in a reaction volume of 50 l by
using the T7-TNT reaction mixture. The reaction mixture was diluted
to 1 ml with Nonidet P-40 lysis buffer, and an aliquot (250 l) was used
for each GST pull-down assay. Two l of the translated reaction mix-
ture was verified by SDS-PAGE and autoradiography. The GST pull-
down assays were performed by incubating equal amounts of GST or
GST fusion protein immobilized to glutathione-Sepharose beads (Am-
ersham Biosciences) with in vitro translated 35S-labeled test protein.
The mixtures were incubated for 2 h at 4 °C and washed six times with
Nonidet P-40 lysis buffer. The bound proteins were eluted with 2 SDS
buffer, separated by SDS-PAGE, and visualized by fluorography (32).
Immunofluorescence and Confocal Imaging—The cells were plated
on glass coverslips in 6-well culture plates. When the cells were 50%
confluent, they were serum-starved for 36 h. Alternatively, 30% conflu-
ent cells were maintained in phenol red-free medium supplemented
with 5% charcoal-striped fetal calf serum for 72 h and treated with
-estradiol (109 M) for 30 min with or without pretreatment with the
anti-estrogen ICI 182780 (108 M) for 1 h. The cells were rinsed in
phosphate-buffered saline, fixed in cold 100% methanol for 10 min, and
processed for immunofluorescent localization of MAT1 and Myc-tagged
MTA1 or ER. The DNA was visualized by counterstaining with ToPro3.
Fluorescent labeling was visualized using a Zeiss LSM 510 microscope
and a 40 objective (32).
Immunohistochemistry—For immunohistochemical detection of
MAT1, the sections were deparaffinized with xylene and rehydrated
using graded ethanol (30). The sections were incubated in 0.3% H2O2
and methanol for 30 min to inactivate endogenous peroxidase. The
sections were then boiled for 10 min in 0.01 M citrate buffer and cooled
for 30 min at room temperature to expose antigenic epitopes. The
sections were sequentially biotin- and protein-blocked and incubated
FIG. 4. Mapping of MTA1 interaction domains of MAT1. A,
schematic representations of MAT1 constructs. N1, amino acids 1–164;
N2, amino acids 1–226; N3, amino acids 1–387; N4, amino acids 1–441;
N5, amino acids 1–535; N6, amino acids 1–630; N7, amino acids 227–
388; N8, amino acids 442–703; N9, amino acids 542–703; and N10,
amino acids 212–715. B, GST pull-down assays using 35S-labeled in
vitro translated MAT1 polypeptides and GST-MTA1 proteins.
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with primary antibody overnight at room temperature followed by
biotinylated secondary antibody, streptavidin-biotin complex, amplifi-
cation reagent, and streptavidin-peroxidase complex (DAKO Corpora-
tion, Carpinteria, CA), and then developed with DAB-H2O2 and coun-
terstained with Mayer’s hematoxylin. Anti-MAT1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) was used at a dilution of 1:100.
Statistical Analysis—Statistical analysis was done using Student’s t
test. The values are considered statistically significant if p  0.05.
RESULTS
Identification of MAT1 as a MTA1-interacting Protein—To
better understand the functions of MTA1 in breast tumor cells,
a yeast two-hybrid screening of the mammary gland cDNA
expression library was performed using the MTA1 C-terminal
amino acids 255–715 as bait. This bait contains several binding
motifs (DNA-binding domain, GATA domain, and SH2 and
SH3 binding domains). As a negative control, we used a re-
cently identified MTA1s variant that lacks protein-binding mo-
tifs as bait (28). Yeast cells expressing the Gal4 fusion protein
were transformed with the above bait. Screening of 2  106
transformants resulted in the isolation of several positive
clones. By sequencing of the positive clones, we identified sev-
eral clones that encoded cDNA of MAT1 (GenBankTM accession
number X92669), an integral component of the CAK complex
(33). The specificity of the MTA1-MAT1 interactions was veri-
fied by one-on-one transformation (Fig. 1A). Interaction was
further confirmed by the growth of the transformed colonies in
medium lacking adenosine, histidine, tryptophan, and leucine
and development of blue coloration in -galactosidase assay,
whereas the cotransfection with the control GBK vector did not
do so (Fig. 1A). Subsequent studies were undertaken to under-
stand the significance of MTA1 interactions with MAT1 in
breast cancer cells.
MAT1 Interacts with MTA1 in Vitro—To confirm the inter-
action between MAT1 and MTA1, we next examined the ability
of in vitro translated MAT1 protein to bind with GST-MTA1 in
vitro. MAT1 interacted efficiently with GST-MTA1 but not with
GST alone in GST pull-down assays (Fig. 1B, left panel). Con-
versely, in vitro translated MTA1 protein also specifically in-
teracted with GST-MAT1 (Fig. 1B, right panel).
MAT1 Interacts with MTA1 in Vivo—To confirm the MAT1
interaction with MTA1 in vivo, MCF-7 cells were cotransfected
with the equal amounts of c-Myc-tagged MTA1 and T7-tagged
MAT1. Immunoprecipitation of cell lysates with an anti-T7
FIG. 5. Mapping of MAT1 interac-
tion domains of MTA1. A, schematic
representations of MAT1 constructs rep-
resenting amino acids 1–189, 1–114,
1–66, 66–309, 189–309, 229–309, and
114–189. B, GST pull-down assays using
35S-labeled in vitro translated MAT1
polypeptides and GST-MTA1 protein.
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antibody was followed by immunoblotting with anti-c-Myc an-
tibody. As illustrated in Fig. 1C, cotransfection with T7-MTA1
but not pCDNA coimmunoprecipitated c-Myc-MTA1. To fur-
ther demonstrate the existence of the noticed interaction be-
tween MAT1 and MTA1 in vivo, we used MCF-7 breast cancer
cells stably expressing T7-tagged MTA1 or pCDNA (7). Immu-
noprecipitation of the endogenous MAT1 with an anti-MAT1
monoclonal antibody was followed by immunoblotting with the
anti-T7 monoclonal antibody. The results showed specific in-
teraction between the endogenous MAT1 and T7-MTA1 in
MCF7/MTA1 cells but not in MCF7/pCDNA cells (Fig. 1D).
Next, we used T47D breast cancer cells that express both
MAT1 as well as MTA1 to demonstrate the interaction between
the endogenous MAT1 and MTA1. Immunoprecipitation of ly-
sate from exponentially growing cells with anti-MTA1 antibody
was followed by Western blotting with anti-MAT1 antibody.
The results show that endogenous MTA1 and endogenous
MAT1 do interact with each other (Fig. 1E).
To explore the spatial relationship between MTA1 and
MAT1 and further validate their interactions in vivo, we uti-
lized immunofluorescence and confocal scanning microscopy.
MCF-7 cells were transiently transfected with Myc-tagged
MTA1 and stained using antibodies against c-Myc antibody to
detect c-Myc-MTA1 (green) or anti-MAT1 antibody to detect the
endogenous MAT1 (red), and DNA was counterstained with the
DNA dye Tropo3 (blue). Areas of colocalization of the red and
green signals show yellow fluorescence (Fig. 1F). In nontrans-
fected cells, MAT1 protein was spread diffusely in the cyto-
plasm and absent from the nucleus (Fig. 1F). This result is in
agreement with previous reports on the subcellular distribu-
tion of MAT1 (33). Transfected MTA1 was concentrated in the
nucleus, as expected (7). Importantly, MAT1 was also concen-
trated in the nucleus selectively in Myc-MTA1 transfected
cells, where it colocalized with Myc-MTA1 (Fig. 1F, right pan-
FIG. 6. MAT1 interaction with ER. A, GST pull-down assay involving in vitro translated 35S-MAT1 was incubated with GST-AF1 or GST-AF2
or GST in the presence and absence of E2. B, GST fusion proteins from five functional domains of ER were incubated with in vitro translated
35S-MAT1 and analyzed by SDS-PAGE and autoradiography. C, MAT1 and ER colocalize following estradiol treatment. MCF-7 cells were grown
in phenol red-free medium supplemented with 3% charcoal-stripped serum for 72 hours and then treated with E2 for 30 min. The cells were fixed
in methanol and immunofluorescently stained for MAT1 (green) and estrogen receptor (red). Areas of colocalization of the red and green signals
show yellow fluorescence. Control cells, MAT1, and ER were diffusely localized in the cytoplasm. E2-treated cells, MAT1, and ER show strong
colocalization at the nuclear periphery and in specific intranuclear regions (40 magnification).
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el). Together, these observations suggested that MAT1 could
interact with Myc-MTA1 under physiological conditions, sug-
gesting the possible influence of MTA1 on the functions of
MAT1 in breast cancer cells.
MAT1 Expression Pattern—To explore the significance of
MAT1 in breast tissues, we examined MAT1 protein expression
levels in normal mouse tissues and human breast cancer cell
lines. MAT1 protein was easily detectable in both ER-positive
(MCF7, ZR75 and T47D) and ER-negative (MDA-MB231,
MDA-MB453 and BT474) cell lines (Fig. 2A). As shown in Fig.
2B, various levels of MAT1 protein were present in many
mouse tissues, with the highest level in the thyroid and mam-
mary glands of pregnant mice (Fig. 2C). To explore the signif-
icance of MAT1 in human breast tumors, we investigated
whether MAT1 protein expression was altered in paired nor-
mal human breast epithelium and breast carcinoma biopsy
samples. As shown in Fig. 3A, MAT1 expression was elevated
in 8 tumors of 12 as compared with the adjacent normal tissue,
which showed either or no expression of MAT1. In 6 of the
MAT1-overexpressing tumors, there was also up-regulation of
MTA1. The blots were reprobed for vinculin as a loading con-
trol. Densitometric scanning of MAT1 and MTA1 protein bands
suggested the existence of statistically significant up-regula-
tion of both proteins in breast tumors as compared with adja-
cent normal appearing tissues (Fig. 3B). To validate these
results, we immunostained paraffin-embedded paired tissue
specimens with an anti-MAT1 monoclonal antibody. Two rep-
resentative examples in Fig. 3C demonstrate an intense MAT1
nuclear staining in tumor tissue, and normal tissue showed no
positive staining.
Mapping of MAT1- and MTA1-interacting Domains—Next,
we defined the minimal region of MTA1 required for its inter-
action with MAT1. MTA1 has several important domains in-
volved in protein-protein interactions, DNA binding, and sig-
naling (Fig. 4A). Several C-terminal MTA1 deletion constructs
were generated and expressed as 35S-labeled proteins and then
subjected to GST pull-down assays with the GST-MAT1 fusion
proteins. The results suggest that amino acids 1–164 of MTA1,
which contain the bromo-domain, and 389–441 amino acids
representing the GATA domain constitute the binding regions
for MAT1 (Fig. 4B). To define the binding region or regions of
MAT1 that are important for MTA1 interaction, we generated
MAT1 encompassing different regions such as N-terminal
RING finger region, the central coiled-coil region, and the C-
terminal cyclin-like box (Fig. 5A). The results of the GST pull-
down assays indicated that MAT1 uses amino acids 1–66 (rep-
resenting the ring finger domain) to interact with MTA1
efficiently (Fig. 5B). These findings demonstrated that MAT1
FIG. 7. MTA1 interacts with CAK
components and ER. Lysates from
MCF-7/pCDNA and MCF-7/T7-MTA1
cells (7) were immunoprecipitated with
antibodies against cyclin H, CDK-7, or
MAT1 and immunoblotted with the indi-
cated antibodies. IP, immunoprecipita-
tion; W, Western blot.
FIG. 8. MAT1 interacts with ER target gene chromatin. A, MCF-7/T7-MTA1 cells (7) treated with estrogen (109 M) for 3–6 h. Then cells
were cross-linked and processed for ChIP assay by using anti-MAT antibody, and PCR was performed. B, MCF-7/pCDNA and MCF-7/T7-MTA1
cells were treated either with estrogen for 3–6 h or with ICI (107 M) for 1 h and then with estrogen for 3–6 h. Subsequently, the cells were
processed for ChIP assay by using anti-MAT antibody or anti-T7 antibody, and PCR was performed. IP, immunoprecipitation.
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binds to the C-terminal 389–441 amino acids GATA domain
and N-terminal 1–164 amino acids bromo-domain of MTA1,
whereas MTA1 binds to the N-terminal ring finger domain of
the MAT1.
MAT1 Interacts with ER—Because repressed MTA1 has
been shown to shown to repress the transactivation functions of
ER (7), we hypothesized that MAT1 might physically interact
with ER and influence its function. To explore this possibility,
we examined the binding ability of in vitro translated MAT1
protein and with the GST-AF1 and AF2 domains of ER in GST
pull-down assays. As shown in Fig. 6A, MAT1 protein effec-
tively interacted with the GST-AF2 (ligand-binding domain of
ER) but not with GST alone or GST-AF1, and this binding was
further increased significantly in the presence of estrogen. To
confirm these results, we performed GST pull-down assays
using various deletion mutants of ER representing domains of
ER and showed that MAT1 interacts with the ligand-binding
region of ER (Fig. 6B).
To determine whether MAT1 and ER would colocalize in
vivo, we examined the immunolocalization of these proteins by
confocal microscopy. MCF-7 cells were grown in estrogen-free
medium for 72 h and then were treated with E2 (109 M) for 30
min. In hormone-depleted cells, both MAT1 (endogenous) and
ER were diffusely localized in the cytoplasm and absent from
the nucleus (Fig. 6C, top panels). However, after E2 treatment,
there was a rapid movement of both proteins to the nuclear
periphery, concentration in specific nuclear regions, and also
diffuse localization in the nucleus (Fig. 6C, middle panels).
Pretreatment of cells with the pure anti-estrogen compound
ICI 182780 completely blocked this dramatic estrogen effect on
MAT1 and ER intracellular localization (Fig. 6C, bottom pan-
els), confirming the ER-mediated nature of the noticed nuclear
colocalization of MAT1 and ER.
MTA1 Interacts with CAK Complex Components—The CAK
complex is composed of CDK7, cyclin H, and MAT1. To dem-
onstrate the endogenous interaction of MTA1 with the compo-
nents of CAK complex, cell lysates from exponentially growing
MCF-7/T7-MTA1 and MCF-7/pcDNA cells (7) were immuno-
precipitated with antibodies against cyclin H, CDK7, and
MAT1. As shown in Fig. 7, MTA1 could be detected in com-
plexes consisting of cyclin H, CDK7, and MAT1 only in MCF-
7/T7-MTA1 and not in vector-transfected MCF-7 cells. Inter-
estingly, both ER and HDAC2 were also present in the CAK1-
MTA1 complex, suggesting a potential role for MTA1 in
modifying (i.e. repressing) the effect of CAK on the transacti-
vation functions of ER.
MAT1 Associates with the ERE-responsive Promoters in
Vivo—To directly demonstrate the potential importance of
MTA1-MAT1 interaction in ERE transcription, we used the
ChIP assay to analyze whether T7-MTA1 or MAT1 associates
with the endogenous ERE-containing promoters. MCF-7/
pcDNA and MCF-7/T7-MTA1 cells were treated with E2 in the
presence or absence of ICI 182780 for 30 min and processed to
formaldehyde cross-link and to sonicated chromatin for immu-
noprecipitation with specific antibodies against T7 or MAT1.
T7-MTA1 or MAT1-bound genomic DNA fragments were ana-
lyzed by quantitative PCR using primers spanning the ERE
elements present in the promoter of the pS2 sequence. The
results indicated that E2 treatment triggered a significant
increase in the amount of pS2 target gene promoter chromatin
associated with T7-MTA1 or MAT1 (Fig. 8). Because both
MAT1 and MTA1 interacted effectively with the ER target gene
chromatin, these findings raised the possibility that MTA1
might influences the status of ER transactivation by MAT1 as
a part of CAK complex. In brief, these findings from Figs. 6 and
8 strongly support the notion that MTA1 might influence the
regulation of ER transactivation function by CAK1-associated
mechanisms.
MTA1 Inhibits CAK Stimulation of ER Transactiva-
tion—To assess the potential significance of noticed MTA1-
MAT1 interactions, we next examined the effect of MTA1 on
the ability of CAK to ER transactivation function in MCF-7
cells. Previous reports have shown that coexpression of all
three components but not individual subunits of CAK1 stim-
ulate transcriptional activity of ER in HeLa cells (27). Con-
sistent with these observations, we observed a significant
stimulation of ERE-dependent transcription by CAK1 in
MCF-7 cells (Fig. 9A). Interestingly, MTA1 expression
blocked the ability of CAK1 to ER-mediated ERE transacti-
vation. Because MTA1 interacts with HDAC2 (7) and because
HDAC2 could be detected in MTA1/CAK1 (Fig. 7) in breast
cancer cells, we reasoned that HDAC inhibition by TSA might
relieve the inhibitory effect of MTA1 on CAK1. Indeed, TSA
treatment of cells was accompanied by a considerable dere-
pression by MTA1. These findings suggested that MTA1
might inhibit CAK-induced transactivation function of ER by
recruiting HDAC.
FIG. 9. MTA1 inhibits CAK-mediated ER transactivation. A,
MCF7 cells were cotransfected with 0.25 g of ERE-luciferase reporter,
0.5 g of MAT1, 0.5 g of MTA1, 0.5 g of CDK7, and 0.5 g of cyclin
H with or without estrogen or TSA stimulation. After 36 h, the cells
were lysed, and luciferase activity was measured (n  3). The activity
was normalized with -galactosidase activity. B, stable clones overex-
pressing pcDNA or MTA1 were transfected with vector alone or CDK7,
cyclin H and MAT1. The cells were maintained in phosphate-free me-
dium before adding [32P]orthophosphosphoric acid to the medium. After
36 h of transfection, the cells were either treated with ethanol or
estradiol (109 M, 2 h). Subsequently cells were lysed and immunopre-
cipitated with anti-estrogen receptor antibody, resolved on a 8% SDS-
PAGE, and taken for autoradiography.
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To further understand the role of MTA1 in the functions of
CAK, we next examined the effect of MTA1 deregulation on the
CAK activity as determined by its ability to phosphorylate ER
in vivo. MCF-7 expressing pcDNA or MTA1 cotransfected with
MAT1 and CDK7 were labeled with [32P]orthophosphoric acid.
The cell lysates were immunoprecipitated with an anti-ER
antibody and analyzed by autoradiography. As expected from
the previous work by Chen et al. (27), CAK expression in
MCF7/pcDNA cells was accompanied by increased phosphoryl-
ation of ER (compare lane 3 with lane 1), which could be further
increased by estrogen treatment (Fig. 9B, compare lane 4 with
lanes 3 and 2). Interesting, the CAK failed to phosphorylate ER
in MCF7/MTA1 cells in both the absence and the presence of
estrogen stimulation (Fig. 9B). These results suggested that
MTA1 deregulation could also impair the ability of CAK to
phosphorylate ER.
DISCUSSION
In the present study, we have identified MAT1, an essential
component of CAK complex with functions in cell cycle control
and transcription, as a MTA1-interacting protein using the
yeast two-hybrid screening. We show that MTA1 interacts with
MAT1 both in vitro and in vivo and that MTA1 could be de-
tected in a complex consisting of CAK components ER and
HDAC in breast cancer cells. In an attempt to understand the
significance of these biochemical interactions, we followed an
earlier finding showing that the CAK complex enhances the ER
transactivation function (27) and demonstrated that estrogen
stimulation of breast cancer cells promotes rapid nuclear trans-
location of MAT1 and its association with the endogenous ER.
Using recombinant proteins, we further demonstrated that
MAT1 directly interacts with the AF2 domain of ER under
basal as well as E2-inducible conditions. In the context of
MTA1, we show that both MTA1 and MAT1 associate with the
ER target gene pS2 promoter chromatin and that MTA1 inhib-
its CAK-induced stimulation of transactivation function of ER.
The functional significance of these findings is derived from the
observations that MAT1 acts as the assembly and targeting
factor of CAK, which regulates transcription including trans-
activation property of ER (27). Because MTA1 expression is
deregulated in human breast tumors (28), it is possible that
MTA1 up-regulation might suppress CAK regulation of the
transactivation activity of ER and, subsequently, leads to loss
of ER responses, which is generally associated with the pro-
gression of breast cancer to more invasive phenotypes. Addi-
tional studies are needed to address these evolving issues.
Inhibition of CAK stimulation of ER transactivation by
MTA1 was presumably due in part to the recruitment of HDAC
to the MTA1-CAK complex, because inhibition could be par-
tially relieved by the HDAC inhibitor TSA. Also the CAK com-
plex in breast cancer cells with deregulated MTA1 contained
HDAC2 (Fig. 7). For the first time, these results show that CAK
complex interacts with an HDAC-interacting corepressor MTA1.
Because both CAK and MTA1 are known to target ER (7, 27), the
findings presented here have revealed the existence of novel
regulatory interactions between MTA1 and CAK and presented a
novel control mechanism for ER transactivation functions in
breast cancer cells. Chen et al. (27) have earlier shown that ER
phosphorylation was induced by CDK7 and MAT1 in presence of
estrogen. Our results are in agreement with that finding. More-
over, in the present study we have also demonstrated that phos-
phorylation of ER could be inhibited as a result of MTA1 overex-
pression both in presence and absence of the ligand. This
illustrates the potential existence of an additional mechanism of
MTA1-induced inhibition of CAK activity.
That the expression of MTA1 and MAT1 could be detected in
ER-negative breast cancer cells and tissues other than the
mammary gland (7) (Fig. 2) is important because it suggests
that MTA1 might also influence the functions of MAT1 and/or
the CAK complex in cellular functions other than ER transac-
tivation. Because MAT1 modulation of CAK activity regulates
cell cycle progression through G1 (24), the effect of MTA1 on
these events in ER-negative breast cancer cells remains to be
investigated in the future studies.
The finding that the ER coactivator MAT1 as a part of the
CAK complex interacts with MTA1, an ER corepressor, is sur-
prising, because it raises the possibility that the final outcome
of the ER transactivation function is influenced by complex
protein-protein interactions rather than by isolated interaction
with one class of proteins. It has been proposed that different
HDAC complexes might be recruited for simple deacetylation of
dynamically regulated ER target gene promoters. The associ-
ated nonenzymatic activities may play a role in determining
the nature of the repression. From our results, it appears that
MTA1 has inhibitory activity against MAT1/CAK-mediated in-
teraction/stimulation of ER transactivation. Because MTA1 ex-
hibited an overall corepressor function in the presence of CAK
and E2 stimulation, these findings suggested an additional
mechanism of MTA1 suppression of ER transactivation in
breast cancer cells.
In summary, the present study identified MAT1 as a target
of corepressor MTA1 and provided new evidence to suggest that
the transactivation functions of ER are influenced by the reg-
ulatory interactions between CAK and MTA1. Our findings are
in agreement with emerging models suggesting the existence of
corepressor and coactivators are in the same complex. This
model suggests that MTA1 and MAT1 might transmodulate
the functions of ER and that any potential deregulation of
MTA1 is likely to contribute to the functional inactivation of
the ER pathway, presumably by recruitment of MTA1 to the
ER target promoter chromatin.
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